Literature DB >> 7913461

Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment.

Y Reiter1, U Brinkmann, S H Jung, B Lee, P G Kasprzyk, C R King, I Pastan.   

Abstract

e23(dsFv)-PE38KDEL is a recombinant immunotoxin composed of the Fv region of anti-erbB2 monoclonal antibody e23 connected to a truncated form of Pseudomonas exotoxin (PE38KDEL), in which the inherently unstable Fv heterodimer (composed of VH and VL) is stabilized by a disulfide bond engineered between structurally conserved framework positions of VH and VL. We have now found that e23(dsFv)-PE38KDEL is considerably more cytotoxic to antigen-positive cell lines than the corresponding single-chain immunotoxin. The basis for the enhanced cytotoxic activity is that the e23 dsFv-immunotoxin binds to erbB2 with greater affinity than the single-chain counterpart. The dsFv-immunotoxin had 4-fold increased binding compared to the scFv and almost identical to the binding affinity of e23 Fab. e23(dsFv)-PE38KDEL was also considerably more stable at 37 degrees C than the single-chain immunotoxin. The therapeutic potential of the disulfide-stabilized immunotoxin was compared with its single-chain counterpart using two animal models of immunodeficient mice bearing subcutaneous tumor xenografts of human gastric tumor N87 cells or human A431 epidermoid carcinoma cells. The antitumor effect of e23(dsFv)-PE38KDEL was significantly better than that of the single-chain immunotoxin. e23(dsFv)-PE38KDEL caused complete regression of tumors at doses which caused no toxic effects in mice, whereas the single-chain immunotoxin did not cause complete regressions at the same doses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913461

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.486


  17 in total

1.  Making artificial antibodies: a format for phage display of combinatorial heterodimeric arrays.

Authors:  C Gao; S Mao; C H Lo; P Wirsching; R A Lerner; K D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

Review 2.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

3.  Disulfide-stabilized single-chain antibody-targeted superantigen: construction of a prokaryotic expression system and its functional analysis.

Authors:  Jian-Li Wang; Yu-Ling Zheng; Ru Ma; Bao-Li Wang; Ai-Guang Guo; Yong-Qiang Jiang
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

4.  Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity.

Authors:  Li Wei; Fan Dongmei; Yang Ming; Shi Ruizan; Yan Yan; Jiang Linlin; Yan Cihui; Li Shuangjing; Wang Min; Wang Jianxiang; Xiong Dongsheng
Journal:  Cell Oncol (Dordr)       Date:  2012-10-09       Impact factor: 6.730

5.  Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties.

Authors:  Christopher M Pirie; Benjamin J Hackel; Michael G Rosenblum; K Dane Wittrup
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

6.  Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.

Authors:  Y Tsutsumi; M Onda; S Nagata; B Lee; R J Kreitman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

7.  Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.

Authors:  P S Chowdhury; J L Viner; R Beers; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

8.  Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma.

Authors:  Zhuqing Li; Sankaranarayana P Mahesh; De Fen Shen; Baoying Liu; Willie O Siu; Frank S Hwang; Qing-Chen Wang; Chi-Chao Chan; Ira Pastan; Robert B Nussenblatt
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

9.  Expression of a Functional zipFv Antibody Fragment and Its Fusions with Alkaline Phosphatase in the Cytoplasm of an Escherichia coli.

Authors:  Byung-Ung Hur; Hyo-Jung Choi; Jae-Bong Yoon; Sang-Hoon Cha
Journal:  Immune Netw       Date:  2010-04-30       Impact factor: 6.303

10.  Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.

Authors:  Rafal Zielinski; Ilya Lyakhov; Amy Jacobs; Oleg Chertov; Gabriela Kramer-Marek; Nicholas Francella; Andrew Stephen; Robert Fisher; Robert Blumenthal; Jacek Capala
Journal:  J Immunother       Date:  2009-10       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.